Loading
A phase 2/3 trial of FAP-2286 in colorectal cancer and ovarian cancer, run by GE Healthcare, now recruiting.
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) is a phase 2/3 interventional study registered as NCT07219238 by GE Healthcare, with 175 participants planned, started 2026-10 and due to reach its primary completion in 2029-06. Interventions recorded: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT). Conditions listed: Colorectal Cancer, Gastric Cancers, Ovarian Cancers, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAP theranostics as a pan-cancer stromal strategy, FAPI PET, Radioligand therapy (beta emitters).
Shares FAPI PET, Ovarian cancer, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/